联系客服

002020 深市 京新药业


首页 公告 京新药业:2014年半年度业绩快报

京新药业:2014年半年度业绩快报

公告日期:2014-07-31

                 证券代码:002020              证券简称:京新药业              公告编号:2014048   

                                浙江京新药业股份有限公司                           

                                    2014年半年度业绩快报                        

                      本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、            

                 误导性陈述或重大遗漏。    

                      特别提示:本公告所载2014半年度的财务数据仅为初步核算数据,已经公司            

                 内部审计部门审计,未经会计师事务所审计,与半年度报告中披露的最终数据可             

                 能存在差异,请投资者注意投资风险。        

                      一、2014半年度主要财务数据和指标      

                                                                                      单位:元  

                                                                                    增减变动幅 

                          项目             本报告期             上年同期          度(%)    

                      营业总收入       594,959,865.86       457,067,669.62          30.17

                       营业利润         69,779,301.25        36,760,216.10          89.82

                       利润总额         69,870,596.44        40,303,486.77          73.36

                    归属于上市公司       59,504,043.49        33,973,459.45          75.15

                     股东的净利润  

                     基本每股收益            0.2355               0.1345             75.09

                         (元)   

                                                                                       增长了 

                    加权平均净资产          7.0543%              4.3201%          2.7342个百  

                         收益率                                                         分点

                                                                                    增减变动幅 

                                           本报告期末           本报告期初         度(%)    

                       总 资 产      1,836,710,693.90    1,324,630,819.08        38.66

                    归属于上市公司  

                    股东的所有者权     1,350,962,078.83      817,978,024.55          65.16

                           益

                       股    本        286,450,919.00       252,662,840.00          13.37

                    归属于上市公司  

                    股东的每股净资           4.7162               3.2374             45.68

                       产(元)   

                 注:上述数据是以公司合并报表数据填列       

                      二、经营业绩和财务状况情况说明      

                      1、经营业绩说明   

                      报告期内,公司经营情况正常,销售收入稳步增长,实现营业总收入                   

                 59495.99万元,比上年同期增长了30.17%,主要是由于公司重点产品市场拓展               

                 有效,成品药和原料药销售收入全面快速增长,其中成品药实现收入30195.66               

                 万元,同比增长32.77%,原料药实现收入27947.11万元,同比增长28.68%。                  

                      报告期内,公司实现营业利润、利润总额和净利润分别为6977.93万元、                

                 6987.06万元和5950.40万元,比上年同期增长了89.82%、73.36%和75.15%。                  

                 主要是由于营业收入增长及产品毛利率上升,导致营业利润及净利润同比增长。              

                      报告期内,基本每股收益0.2355元,比上年同期增长了75.09%,主要是净               

                 利润同比增长75.15%所致。     

                      2、财务状况说明   

                      报告期末,公司财务状况良好,总资产183,671.07万元,比年初增长                   

                 38.66%;归属于上市公司股东的所有者权益135,096.21万元,比年初增长                   

                 65.16%;归属于上市公司股东的每股净资产4.7162元,比年初增长45.68%;主                

                 要是公司于2014年6月非公开发行A股股票33,788,079股,公司资产、所有者                 

                 权益增加所致。   

                      三、与前次业绩预计的差异说明      

                      公司 2014 年第一季度报告中对2014     年1-6 月预计的经营业绩为:归属于     

                 上市公司股东的净利润变动区间为5100至6150万元,本次业绩快报披露的经营业            

                 绩与前次披露的“2014     年第一季度季度报告”中预计的业绩不存在差异。         

                      四、业绩泄漏原因和股价异动情况分析       

                      不适用。  

                      五、其他说明   

                      无。 

                      六、备查文件   

                      1、经公司现任法定代表人、主管会计工作的负责人、会计机构负责人(会               

                 计主管人员)签字并盖章的比较式资产负债表和利润表;          

                      2、内部审计部门负责人签字的内部审计报告。         

                      特此公告。  

                                                            浙江京新药业股份有限公司董事会     

                                                                      二O一四年七月三十一日